Download PDF
Semin Neurol 2017; 37(03): 316-325
DOI: 10.1055/s-0037-1603468
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Prevention of Cerebral Small Vessel Disease

Eric E. Smith
1   Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
› Author Affiliations
Further Information

Publication History

Publication Date:
31 July 2017 (online)

    Permissions and Reprints

Abstract

Cerebral small vessel disease can cause either ischemic stroke or intracerebral hemorrhage. Accounting for up to 25% of all strokes, it is also the second biggest contributor to the risk of dementia, and is the most common incidentally discovered finding on brain imaging. There are two main causes of cerebral small vessel disease: arteriolosclerotic small vessel disease (with hypertension as the main modifiable risk factor) and cerebral amyloid angiopathy (predominantly caused by β-amyloid deposits limited to the cerebral small arteries, arterioles, and capillaries). Prevention should include the treatment of hypertension and diabetes, if present, and the modification of lifestyle factors such as obesity and poor nutrition. Patients with small subcortical ischemic strokes should be treated with antithrombotics; dual antiplatelet therapy may be more effective than aspirin for the first 3 weeks following acute stroke, but is not more effective than aspirin for long-term prevention. Unresolved questions include the effectiveness of nonaspirin prevention strategies to prevent early recurrence or stroke extension in small subcortical ischemic stroke, and whether symptomatic or silent small vessel disease should influence decisions regarding selection for carotid revascularization or anticoagulation for atrial fibrillation. There is an unmet need for disease-modifying preventive therapies for cerebral amyloid angiopathy, the second most-common cause of spontaneous intracerebral hemorrhage.

Keywords

ischemic stroke - prevention - leukoaraiosis - lacunar infarct - lacunar syndrome - intracerebral hemorrhage - cerebral amyloid angiopathy
 

  • References

  • 1 Wardlaw JM, Smith EE, Biessels GJ. , et al; STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013; 12 (08) 822-838
    CrossrefPubMedGoogle Scholar
  • 2 Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010; 9 (07) 689-701
    CrossrefPubMedGoogle Scholar
  • 3 Charidimou A, Pantoni L, Love S. The concept of sporadic cerebral small vessel disease: A road map on key definitions and current concepts. Int J Stroke 2016; 11 (01) 6-18
    CrossrefPubMedGoogle Scholar
  • 4 Boulouis G, Charidimou A, Greenberg SM. Sporadic cerebral amyloid angiopathy: Pathophysiology, neuroimaging features, and clinical implications. Semin Neurol 2016; 36 (03) 233-243
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Revesz T, Holton JL, Lashley T. , et al. Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. Acta Neuropathol 2009; 118 (01) 115-130
    CrossrefPubMedGoogle Scholar
  • 6 Neuropathology Group. Medical Research Council Cognitive Function and Aging Study; Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 2001; 357 (9251): 169-175
    CrossrefPubMedGoogle Scholar
  • 7 Chen YW, Lee MJ, Smith EE. Cerebral amyloid angiopathy in East and West. Int J Stroke 2010; 5 (05) 403-411
    CrossrefPubMedGoogle Scholar
  • 8 Rannikmäe K, Samarasekera N, Martînez-Gonzâlez NA, Al-Shahi Salman R, Sudlow CL. Genetics of cerebral amyloid angiopathy: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2013; 84 (08) 901-908
    CrossrefPubMedGoogle Scholar
  • 9 Grau AJ, Weimar C, Buggle F. , et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke 2001; 32 (11) 2559-2566
    CrossrefPubMedGoogle Scholar
  • 10 Gan R, Sacco RL, Kargman DE, Roberts JK, Boden-Albala B, Gu Q. Testing the validity of the lacunar hypothesis: the Northern Manhattan Stroke Study experience. Neurology 1997; 48 (05) 1204-1211
    CrossrefPubMedGoogle Scholar
  • 11 Meschia JF, Bushnell C, Boden-Albala B. , et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Functional Genomics and Translational Biology; Council on Hypertension. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45 (12) 3754-3832
    CrossrefPubMedGoogle Scholar
  • 12 Baigent C, Blackwell L, Collins R. , et al; Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373 (9678): 1849-1860
    CrossrefPubMedGoogle Scholar
  • 13 Fang MC, Go AS, Chang Y. , et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007; 120 (08) 700-705
    CrossrefPubMedGoogle Scholar
  • 14 Smith EE. Subclinical Vascular Brain Injury. In: Ovbiagele O. ed, Ischemic Stroke Therapeutics. 1 ed. New York: Springer International Publishing; 2016: 265-275
    Google Scholar
  • 15 Gorelick PB, Scuteri A, Black SE. , et al; American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42 (09) 2672-2713
    CrossrefPubMedGoogle Scholar
  • 16 Smith EE, Saposnik G, Biessels GJ. , et al; American Heart Association Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Functional Genomics and Translational Biology; and Council on Hypertension. Prevention of Stroke in Patients With Silent Cerebrovascular Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2017; 48 (02) e44-e71
    CrossrefPubMedGoogle Scholar
  • 17 Smith EE, Schneider JA, Wardlaw JM, Greenberg SM. Cerebral microinfarcts: the invisible lesions. Lancet Neurol 2012; 11 (03) 272-282
    CrossrefPubMedGoogle Scholar
  • 18 Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM. Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 2002; 33 (01) 21-25
    CrossrefPubMedGoogle Scholar
  • 19 Fanning JP, Wong AA, Fraser JF. The epidemiology of silent brain infarction: a systematic review of population-based cohorts. BMC Med 2014; 12: 119
    CrossrefPubMedGoogle Scholar
  • 20 Hasegawa Y, Yamaguchi T, Omae T, Woodward M, Chalmers J. ; PROGRESS CT Substudy Investigators. Effects of perindopril-based blood pressure lowering and of patient characteristics on the progression of silent brain infarct: the Perindopril Protection against Recurrent Stroke Study (PROGRESS) CT Substudy in Japan. Hypertens Res 2004; 27 (03) 147-156
    CrossrefPubMedGoogle Scholar
  • 21 Fernando MS, O'Brien JT, Perry RH. , et al; Neuropathology Group of MRC CFAS. Comparison of the pathology of cerebral white matter with post-mortem magnetic resonance imaging (MRI) in the elderly brain. Neuropathol Appl Neurobiol 2004; 30 (04) 385-395
    CrossrefPubMedGoogle Scholar
  • 22 Liao D, Cooper L, Cai J. , et al. The prevalence and severity of white matter lesions, their relationship with age, ethnicity, gender, and cardiovascular disease risk factors: the ARIC Study. Neuroepidemiology 1997; 16 (03) 149-162
    CrossrefPubMedGoogle Scholar
  • 23 Dufouil C, de Kersaint-Gilly A, Besançon V. , et al. Longitudinal study of blood pressure and white matter hyperintensities: the EVA MRI Cohort. Neurology 2001; 56 (07) 921-926
    CrossrefPubMedGoogle Scholar
  • 24 Dufouil C, Chalmers J, Coskun O. , et al; PROGRESS MRI Substudy Investigators. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation 2005; 112 (11) 1644-1650
    CrossrefPubMedGoogle Scholar
  • 25 Weber R, Weimar C, Blatchford J. , et al; PRoFESS Imaging Substudy Group. Telmisartan on top of antihypertensive treatment does not prevent progression of cerebral white matter lesions in the prevention regimen for effectively avoiding second strokes (PRoFESS) MRI substudy. Stroke 2012; 43 (09) 2336-2342
    CrossrefPubMedGoogle Scholar
  • 26 Mok VC, Lam WW, Fan YH. , et al. Effects of statins on the progression of cerebral white matter lesion: Post hoc analysis of the ROCAS (Regression of Cerebral Artery Stenosis) study. J Neurol 2009; 256 (05) 750-757
    CrossrefPubMedGoogle Scholar
  • 27 Xiong Y, Wong A, Cavalieri M. , et al. Prestroke statins, progression of white matter hyperintensities, and cognitive decline in stroke patients with confluent white matter hyperintensities. Neurotherapeutics 2014; 11 (03) 606-611
    CrossrefPubMedGoogle Scholar
  • 28 ten Dam VH, van den Heuvel DM, van Buchem MA. , et al; PROSPER Study Group. Effect of pravastatin on cerebral infarcts and white matter lesions. Neurology 2005; 64 (10) 1807-1809
    CrossrefPubMedGoogle Scholar
  • 29 Cavalieri M, Schmidt R, Chen C. , et al; VITATOPS Trial Study Group. B vitamins and magnetic resonance imaging-detected ischemic brain lesions in patients with recent transient ischemic attack or stroke: the VITAmins TO Prevent Stroke (VITATOPS) MRI-substudy. Stroke 2012; 43 (12) 3266-3270
    CrossrefPubMedGoogle Scholar
  • 30 Launer LJ, Miller ME, Williamson JD. , et al; ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol 2011; 10 (11) 969-977
    CrossrefPubMedGoogle Scholar
  • 31 Richard E, Gouw AA, Scheltens P, van Gool WA. Vascular care in patients with Alzheimer disease with cerebrovascular lesions slows progression of white matter lesions on MRI: the evaluation of vascular care in Alzheimer's disease (EVA) study. Stroke 2010; 41 (03) 554-556
    CrossrefPubMedGoogle Scholar
  • 32 Greenberg SM, Vernooij MW, Cordonnier C. , et al; Microbleed Study Group. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol 2009; 8 (02) 165-174
    CrossrefPubMedGoogle Scholar
  • 33 Cheng AL, Batool S, McCreary CR. , et al. Susceptibility-weighted imaging is more reliable than T2*-weighted gradient-recalled echo MRI for detecting microbleeds. Stroke 2013; 44 (10) 2782-2786
    CrossrefPubMedGoogle Scholar
  • 34 Akoudad S, Portegies ML, Koudstaal PJ. , et al. Cerebral Microbleeds Are Associated With an Increased Risk of Stroke: The Rotterdam Study. Circulation 2015; 132 (06) 509-516
    CrossrefPubMedGoogle Scholar
  • 35 O'Donnell MJ, Eikelboom JW, Yusuf S. , et al. Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study. Am Heart J 2016; 178: 145-150
    CrossrefPubMedGoogle Scholar
  • 36 Doubal FN, MacLullich AM, Ferguson KJ, Dennis MS, Wardlaw JM. Enlarged perivascular spaces on MRI are a feature of cerebral small vessel disease. Stroke 2010; 41 (03) 450-454
    CrossrefPubMedGoogle Scholar
  • 37 Maclullich AM, Wardlaw JM, Ferguson KJ, Starr JM, Seckl JR, Deary IJ. Enlarged perivascular spaces are associated with cognitive function in healthy elderly men. J Neurol Neurosurg Psychiatry 2004; 75 (11) 1519-1523
    CrossrefPubMedGoogle Scholar
  • 38 Fisher CM. The arterial lesions underlying lacunes. Acta Neuropathol 1968; 12 (01) 1-15
    PubMedGoogle Scholar
  • 39 Moreau F, Patel S, Lauzon ML. , et al. Cavitation after acute symptomatic lacunar stroke depends on time, location, and MRI sequence. Stroke 2012; 43 (07) 1837-1842
    CrossrefPubMedGoogle Scholar
  • 40 Fisher CM. Lacunar strokes and infarcts: a review. Neurology 1982; 32 (08) 871-876
    CrossrefPubMedGoogle Scholar
  • 41 Yoon Y, Lee DH, Kang DW, Kwon SU, Kim JS. Single subcortical infarction and atherosclerotic plaques in the middle cerebral artery: high-resolution magnetic resonance imaging findings. Stroke 2013; 44 (09) 2462-2467
    CrossrefPubMedGoogle Scholar
  • 42 Ay H, Oliveira-Filho J, Buonanno FS. , et al. Diffusion-weighted imaging identifies a subset of lacunar infarction associated with embolic source. Stroke 1999; 30 (12) 2644-2650
    CrossrefPubMedGoogle Scholar
  • 43 Kwok CS, Shoamanesh A, Copley HC, Myint PK, Loke YK, Benavente OR. Efficacy of antiplatelet therapy in secondary prevention following lacunar stroke: pooled analysis of randomized trials. Stroke 2015; 46 (04) 1014-1023
    CrossrefPubMedGoogle Scholar
  • 44 Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, Pearce LA. ; SPS3 Investigators. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012; 367 (09) 817-825
    CrossrefPubMedGoogle Scholar
  • 45 Wang Y, Wang Y, Zhao X. , et al; CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013; 369 (01) 11-19
    CrossrefPubMedGoogle Scholar
  • 46 Johnston SC, Easton JD, Farrant M. , et al. Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design. Int J Stroke 2013; 8 (06) 479-483
    CrossrefPubMedGoogle Scholar
  • 47 Benavente OR, Coffey CS, Conwit R. , et al; SPS3 Study Group. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 2013; 382 (9891): 507-515
    CrossrefPubMedGoogle Scholar
  • 48 Kelly J, Hunt BJ, Rudd A, Lewis RR. Should patients with lacunar stroke and severe carotid artery stenosis undergo endarterectomy?. QJM 2002; 95 (05) 313-319
    CrossrefPubMedGoogle Scholar
  • 49 Evans A, Perez I, Yu G, Kalra L. Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation?. Stroke 2001; 32 (12) 2828-2832
    CrossrefPubMedGoogle Scholar
  • 50 Smith EE, Rosand J, Knudsen KA, Hylek EM, Greenberg SM. Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke. Neurology 2002; 59 (02) 193-197
    CrossrefPubMedGoogle Scholar
  • 51 Kernan WN, Ovbiagele B, Black HR. , et al; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45 (07) 2160-2236
    CrossrefPubMedGoogle Scholar
  • 52 Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF. Spontaneous intracerebral hemorrhage. N Engl J Med 2001; 344 (19) 1450-1460
    CrossrefPubMedGoogle Scholar
  • 53 Vinters HV, Gilbert JJ. Cerebral amyloid angiopathy: incidence and complications in the aging brain. II. The distribution of amyloid vascular changes. Stroke 1983; 14 (06) 924-928
    CrossrefPubMedGoogle Scholar
  • 54 Linn J, Halpin A, Demaerel P. , et al. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology 2010; 74 (17) 1346-1350
    CrossrefPubMedGoogle Scholar
  • 55 Khurram A, Kleinig T, Leyden J. Clinical associations and causes of convexity subarachnoid hemorrhage. Stroke 2014; 45 (04) 1151-1153
    CrossrefPubMedGoogle Scholar
  • 56 Charidimou A, Linn J, Vernooij MW. , et al. Cortical superficial siderosis: detection and clinical significance in cerebral amyloid angiopathy and related conditions. Brain 2015; 138 (Pt 8): 2126-2139
    CrossrefPubMedGoogle Scholar
  • 57 Viswanathan A, Rakich SM, Engel C. , et al. Antiplatelet use after intracerebral hemorrhage. Neurology 2006; 66 (02) 206-209
    CrossrefPubMedGoogle Scholar
  • 58 Hemphill III JC, Greenberg SM, Anderson CS. , et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology. Guidelines for the management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals From the American Heart Association/American Stroke Association. Stroke 2015; 46 (07) 2032-2060
    CrossrefPubMedGoogle Scholar
  • 59 Majeed A, Kim YK, Roberts RS, Holmström M, Schulman S. Optimal timing of resumption of warfarin after intracranial hemorrhage. Stroke 2010; 41 (12) 2860-2866
    CrossrefPubMedGoogle Scholar
  • 60 Eckman MH, Rosand J, Knudsen KA, Singer DE, Greenberg SM. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke 2003; 34 (07) 1710-1716
    CrossrefPubMedGoogle Scholar
  • 61 Ruff CT, Giugliano RP, Braunwald E. , et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383 (9921): 955-962
    CrossrefPubMedGoogle Scholar
  • 62 Connolly SJ, Eikelboom J, Joyner C. , et al; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364 (09) 806-817
    CrossrefPubMedGoogle Scholar
  • 63 White L. Brain lesions at autopsy in older Japanese-American men as related to cognitive impairment and dementia in the final years of life: a summary report from the Honolulu-Asia aging study. J Alzheimers Dis 2009; 18 (03) 713-725
    CrossrefPubMedGoogle Scholar
  • 64 Sachdev P, Kalaria R, O'Brien J. , et al; Internationlal Society for Vascular Behavioral and Cognitive Disorders. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord 2014; 28 (03) 206-218
    CrossrefPubMedGoogle Scholar
  • 65 Satizabal CL, Beiser AS, Chouraki V, Chêne G, Dufouil C, Seshadri S. Incidence of dementia over three decades in the Framingham Heart Study. N Engl J Med 2016; 374 (06) 523-532
    CrossrefPubMedGoogle Scholar
  • 66 Schrijvers EM, Verhaaren BF, Koudstaal PJ, Hofman A, Ikram MA, Breteler MM. Is dementia incidence declining?: Trends in dementia incidence since 1990 in the Rotterdam Study. Neurology 2012; 78 (19) 1456-1463
    CrossrefPubMedGoogle Scholar